No Data
No Data
Express News | Tnf Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
TNF Pharmaceuticals Announces New Board and Shareholder Votes
TNF Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Eagle EGRX Delist; TNF Pharmaceuticals TNFA Equity Investment
Express News | Tnf Pharmaceuticals Inc - Fully Funded for Clinical Trials for Next Two Years
No Data